At present, clinical trials on the effect of NRF2 agonists on diabetic nephropathy, CKD, or other kidney diseases have been completed or are underway (NCT03550443, NCT03019185, NCT03749447, NCT03366337, and NCT03918447). The gene discussed is NFE2L2; the disease is kidney disorder.